Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.

Participants were positive about ctDNA monitoring and early treatment and would welcome extra surveillance, as well as trust ctDNA tests. This indicates the feasibility of the wider implementation of ctDNA tests, which have applicability for many tumour types and disease stages.